Cell-Free DNA BloodCollection Tube

Early Cancer Screening
By collecting blood with cell – free DNA blood collection tubes, the circulating tumor DNA (ctDNA) in the blood can be collected. Detecting abnormalities such as gene mutations and methylation related to tumors can help identify lesions at an early stage when the tumor is still small and asymptomatic. For example, detecting mutations in genes such as EGFR and KRAS is helpful for the early detection of lung cancer, colorectal cancer, etc.
Cancer Treatment Efficacy Monitoring
During cancer treatment, blood is regularly collected using cell – free DNA blood collection tubes to dynamically monitor changes in ctDNA. If the treatment is effective, the ctDNA level usually decreases; if recurrence or drug resistance occurs, the ctDNA level may rise again, enabling doctors to adjust the treatment plan in a timely manner.
Cancer Molecular Typing
Analyzing the gene characteristics in cell – free DNA helps in the molecular typing of tumors, providing a basis for precision medicine. For example, determining whether breast cancer is HER2 – positive, triple – negative, etc., guides the use of targeted drugs such as trastuzumab.

Detection of Fetal Chromosomal Abnormalities
Fetal – derived cell – free DNA exists in the peripheral blood of pregnant women. By collecting the blood of pregnant women with cell – free DNA blood collection tubes, non – invasive prenatal testing (NIPT) can be carried out to detect whether the fetus has chromosomal number abnormalities such as trisomy 21, trisomy 18, and trisomy 13. It is a safe and effective prenatal screening method that reduces the risks of miscarriage and other complications caused by invasive examinations such as amniocentesis.
Detection of Monogenic Genetic Diseases
For some monogenic genetic diseases with known pathogenic genes, such as thalassemia and hemophilia, the gene sequence of the fetus in the cell – free DNA can be analyzed to determine whether the fetus carries the pathogenic gene, providing important information for prenatal diagnosis and genetic counseling.

Transplant Rejection Monitoring
After organ transplantation, donor – derived cell – free DNA appears in the recipient’s blood. By collecting blood with cell – free DNA blood collection tubes and monitoring the content and changes of donor – derived cell – free DNA, transplant rejection can be detected at an early stage. When rejection occurs, the level of donor – derived cell – free DNA often increases, helping doctors take timely intervention measures.
Assessment of Graft Injury
Combined with other clinical indicators, analyzing the characteristics of cell – free DNA can evaluate the injury of the graft, determine whether there is ischemia – reperfusion injury, immune injury, etc., and provide a reference for adjusting the immunosuppressive regimen.

Pathogen Detection
In some infectious diseases, the DNA of the pathogen is released into the blood. After collecting blood using cell – free DNA blood collection tubes, the DNA of the pathogen can be detected through gene detection techniques, such as detecting hepatitis B virus DNA and Mycobacterium tuberculosis DNA, which is used for disease diagnosis, treatment efficacy evaluation, and prognosis judgment.
Assessment of Infection and Inflammatory State
The level and characteristics of cell – free DNA may be related to the severity of the infection and the state of the inflammatory response. It can be used as an auxiliary indicator to help doctors comprehensively understand the patient’s condition, judge whether the infection is under control, and whether the inflammation has subsided.